Current methods to differentiate cardiomyocytes from human pluripotent stem cells (PSCs)
inadequately recapitulate complete development and result in PSC-derived cardiomyocytes …

The human heart is considered a non-regenerative organ. Worldwide, cardiovascular
diseases continue to be the leading cause of death. Despite advances in cardiac treatment …

Since the advent of the generation of human induced pluripotent stem cells (hiPSCs),
numerous protocols have been developed to differentiate hiPSCs into cardiomyocytes and …

Human pluripotent stem cell (hPSC)-derived endothelial cells and their progenitors may
provide the means for vascularization of tissue-engineered constructs and can serve as …

Background: Reprogramming of cardiac fibroblasts into induced cardiomyocyte-like cells in
situ represents a promising strategy for cardiac regeneration. A combination of 3 cardiac …

Human pluripotent stem cells (hPSCs) provide a valuable model for the study of human
development and a means to generate a scalable source of cells for therapeutic …

Cell therapies treating pathological muscle atrophy or damage requires an adequate
quantity of muscle progenitor cells (MPCs) not currently attainable from adult donors. Here …

Cardiovascular diseases remain the leading cause of death worldwide; hence there is an
increasing focus on developing physiologically relevant in vitro cardiovascular tissue …

Endothelial cells (ECs) in the central nervous system (CNS) acquire their specialized blood–
brain barrier (BBB) properties in response to extrinsic signals, with Wnt/β-catenin signaling …

Differentiation of cardiomyocytes (CMs) from human induced pluripotent stem cells (hiPSCs)
is critically dependent upon the regulation of the Wnt signaling pathway. The mechanisms …